Tech Session V: Nanomedicine and Nanoscale Delivery (Focus: Oral)

Thursday, July 17, 2025

10:00 AM - 12:00 PM EDT

Location: 121 B/C

Chair(s)

Stefano Salmaso, PhD (he/him/his)

Professor
Department of Pharmaceutical Sciences
University of Padova
Padova, Italy

Co-Chair(s)

Yahya Choonara, BPharm, MPharm, PhD (he/him/his)

Professor
Pharmacy and Pharmacology
University of the Witwatersrand
Johannesburg, Gauteng, South Africa

Development, physicochemical and biological characterization, in vivo validation, delivery of therapeutics, functionalization with active-targeting moieties, long-acting formulations, controlled release, injectables, implantables. (Focus: Oral)

Presentations:

10:04 AM - 10:29 AM EDT

Magneto-responsive drug delivery systems for local treatment of colorectal cancer
Invited Speaker: Alexandra Teleki, PhD (she/her/hers) – Uppsala University
10:29 AM - 10:54 AM EDT

NAC-based Ionic Liquids for GLP-1 Delivery: A Mechanistic Understanding of In Vivo Performance
Invited Speaker - Exceptional Abstract: Zhigao Niu (he/him/his) – Novo Nordisk
10:54 AM - 11:05 AM EDT

Intestinal Fc receptor-targeted nanomedicines boost semaglutide effect in type 2 diabetes
Oral Abstract Speaker: Soraia FT Pinto, PhD (she/her/hers) – Institute for Research and Innovation in Health (i3S), University of Porto, Portugal
11:05 AM - 11:16 AM EDT

Oral delivery of MSC-EVs as a novel approach to treat inflammatory bowel disease
Oral Abstract Speaker: Mona Belaid (she/her/hers) – King's College London and National University of Singapore
11:16 AM - 11:27 AM EDT

Predicting Drug Delivery of Push Pull OROS: A Biorelevant Dissolution and PK Simulation Strategy
Oral Abstract Speaker: Grzegorz Z. Garbacz, g.garbacz@physiolution.pl (he/him/his) – Physiolution
11:38 AM - 11:49 AM EDT

Transforming Healthcare: Treatment of Inflammatory Bowel Disease with Biocatalytic Nanobots
Oral Abstract Speaker: Ana Sofia Sousa, MSc (she/her/hers) – Universidade Católica Portuguesa
11:49 AM - 12:00 PM EDT

Improving bioavailability of poorly soluble oral drugs
Oral Abstract Speaker: Taslima Binte Kamal – University of New South Wales